Frontiers in Medicine (Aug 2022)

Case report: Bladder preserving after maximal transurethral resection of the bladder tumor combined with chemotherapy and immunotherapy in recurrent muscle-invasive bladder cancer patients: A report of two cases

  • Jiaquan Mao,
  • Jiaquan Mao,
  • Chunguang Yang,
  • Chunguang Yang,
  • Sheng Xin,
  • Sheng Xin,
  • Kai Cui,
  • Kai Cui,
  • Zheng Liu,
  • Zheng Liu,
  • Tao Wang,
  • Tao Wang,
  • Zhiquan Hu,
  • Zhiquan Hu,
  • Shaogang Wang,
  • Shaogang Wang,
  • Jihong Liu,
  • Jihong Liu,
  • Xiaodong Song,
  • Xiaodong Song,
  • Wen Song,
  • Wen Song

DOI
https://doi.org/10.3389/fmed.2022.949567
Journal volume & issue
Vol. 9

Abstract

Read online

BackgroundCisplatin-based neoadjuvant chemotherapy combined with radical cystectomy (RC) plus pelvic lymph node dissection (PLND) is the preferred treatment option for muscle-invasive bladder cancer (MIBC). However, some patients are unable to tolerate RC or may have postoperative complications after RC. And most patients have a strong desire for bladder-preserving treatment. There are no reports on the efficacy of maximal transurethral resection of the bladder tumor (TURBT) in combination with chemotherapy plus tislelizumab for bladder-preserving in recurrent MIBC patients.Case presentationWe report two cases diagnosed with recurrent MIBC who achieved pathological complete response (pCR) and bladder-preserving after maximal TURBT combined with chemotherapy plus tislelizumab.ConclusionPostoperative immunotherapy should be considered for all patients with recurrent MIBC who are eligible for immunotherapy. In addition, high programmed death ligand-1 (PD-L1) expression, high tumor mutation burden (TMB), and TP53 mutation level can be combined to predict tislelizumab efficacy.

Keywords